KR101380360B1 - 거대세포바이러스 감염의 치료를 위한, 단독으로 또는 피티엑스 3 또는 강시클로비어와 병용되는 티모신 알파1의 용도 - Google Patents

거대세포바이러스 감염의 치료를 위한, 단독으로 또는 피티엑스 3 또는 강시클로비어와 병용되는 티모신 알파1의 용도 Download PDF

Info

Publication number
KR101380360B1
KR101380360B1 KR1020087029405A KR20087029405A KR101380360B1 KR 101380360 B1 KR101380360 B1 KR 101380360B1 KR 1020087029405 A KR1020087029405 A KR 1020087029405A KR 20087029405 A KR20087029405 A KR 20087029405A KR 101380360 B1 KR101380360 B1 KR 101380360B1
Authority
KR
South Korea
Prior art keywords
thymosin alpha
ptx3
mice
virus
infection
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020087029405A
Other languages
English (en)
Korean (ko)
Other versions
KR20090007621A (ko
Inventor
루이지나 로마니
프랑세스코 비스토니
엔리코 가라시
Original Assignee
시그마타우 인두스트리에 파르마슈티케 리우니테 에스.피.에이.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 시그마타우 인두스트리에 파르마슈티케 리우니테 에스.피.에이. filed Critical 시그마타우 인두스트리에 파르마슈티케 리우니테 에스.피.에이.
Publication of KR20090007621A publication Critical patent/KR20090007621A/ko
Application granted granted Critical
Publication of KR101380360B1 publication Critical patent/KR101380360B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2292—Thymosin; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Endocrinology (AREA)
  • Communicable Diseases (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020087029405A 2006-05-02 2007-04-12 거대세포바이러스 감염의 치료를 위한, 단독으로 또는 피티엑스 3 또는 강시클로비어와 병용되는 티모신 알파1의 용도 Expired - Fee Related KR101380360B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP06113401 2006-05-02
EP06113401.1 2006-05-02
PCT/EP2007/053574 WO2007128647A1 (en) 2006-05-02 2007-04-12 USE OF THYMOSIN α1, ALONE OR IN COMBINATION WITH PTX3 OR GANCICLOVIR, FOR THE TREATMENT OF CYTOMEGALOVIRUS INFECTION

Publications (2)

Publication Number Publication Date
KR20090007621A KR20090007621A (ko) 2009-01-19
KR101380360B1 true KR101380360B1 (ko) 2014-04-09

Family

ID=36658736

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020087029405A Expired - Fee Related KR101380360B1 (ko) 2006-05-02 2007-04-12 거대세포바이러스 감염의 치료를 위한, 단독으로 또는 피티엑스 3 또는 강시클로비어와 병용되는 티모신 알파1의 용도

Country Status (18)

Country Link
US (1) US8337828B2 (enExample)
EP (1) EP2012816B1 (enExample)
JP (1) JP5441685B2 (enExample)
KR (1) KR101380360B1 (enExample)
CN (1) CN101437535B (enExample)
AU (1) AU2007247292B2 (enExample)
BR (1) BRPI0711136A2 (enExample)
CA (1) CA2649063C (enExample)
CY (1) CY1113277T1 (enExample)
DK (1) DK2012816T3 (enExample)
ES (1) ES2389452T3 (enExample)
HR (1) HRP20120676T1 (enExample)
MX (1) MX2008013872A (enExample)
PL (1) PL2012816T3 (enExample)
PT (1) PT2012816E (enExample)
RS (1) RS52377B (enExample)
SI (1) SI2012816T1 (enExample)
WO (1) WO2007128647A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1298487B1 (it) * 1997-12-19 2000-01-10 Sigma Tau Ind Farmaceuti Composizioni farmaceutiche comprendenti pentraxina lunga ptx3 per la terapia di patologie di tipo infettivo, infiammatorio o tumorale,
ITRM20040223A1 (it) * 2004-05-07 2004-08-07 Sigma Tau Ind Farmaceuti Medicamento per il trattamento delle infezioni fungine, in particolare dell'aspergillosi.
EP1832295A1 (en) * 2006-03-10 2007-09-12 Tecnogen S.P.A. Use of PTX3 for the treatment of viral diseases
US8829173B2 (en) * 2008-09-26 2014-09-09 Tocagen Inc. Recombinant vectors
CN102458470B (zh) * 2009-05-08 2016-01-20 赛生制药有限公司 作为疫苗增强剂的α胸腺素肽
EP2675272A4 (en) * 2011-02-09 2015-03-11 Sciclone Pharmaceuticals Inc THYMOSINE ALPHA PEPTIDE FOR THE PREVENTION, TREATMENT AND TREATMENT OF INFECTIONS
JP6419706B2 (ja) 2012-10-25 2018-11-07 トカジェン インコーポレーテッド ミニプロモーターカセットを含むレトロウイルスベクター

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999032516A2 (en) * 1997-12-19 1999-07-01 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Pharmaceutical compositions containing the long pentraxin ptx3
US20010012830A1 (en) * 1993-06-02 2001-08-09 Sciclone Pharmaceuticals, Inc. Combination therapy method for treating chronic hepatitis B
WO2004094991A2 (en) * 2003-04-23 2004-11-04 Sciclone Pharmaceuticals, Inc. Treatment or prevention of respiratory viral infections with alpha thymosin peptides

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6106868A (en) 1990-08-24 2000-08-22 The Board Of Governors Of Wayne State University Method for the treatment of hepatitis
TW224053B (enExample) * 1991-09-13 1994-05-21 Paul B Chretien
CN1072961C (zh) * 1993-03-05 2001-10-17 施塞克龙药品公司 治疗对干扰素治疗无反应者的丙型肝炎的方法
US5632983A (en) * 1994-11-17 1997-05-27 University Of South Florida Method for treating secondary immunodeficiency
WO1998018491A1 (en) * 1996-10-28 1998-05-07 BURGSTINER, Jacqueline, Cook Methods and compositions for dietary supplementation
US5939423A (en) 1997-04-16 1999-08-17 Sciclone Pharmaceuticals, Inc. Treatment of hepatitis B infection with thymosin alpha 1 and famciclovir
US6288033B1 (en) 1998-09-25 2001-09-11 Sciclone Pharmaceuticals, Inc. Treatment of hepatitis B infection with thymosin alpha 1 in combination with lamivudine or in combination with lamivudine and famciclovir
IT1317927B1 (it) 2000-11-03 2003-07-15 Sigma Tau Ind Farmaceuti Uso della pentraxina lunga ptx3 per la preparazione di un medicamentoper il trattamento di patologie autoimmuni.
IT1317930B1 (it) 2000-11-08 2003-07-15 Sigma Tau Ind Farmaceuti Uso della pentraxina lunga ptx3 per la preparazione di un medicamentoper il trattamento di patalogie associate ad una alterata attivazione
PT1411971E (pt) 2001-08-03 2006-07-31 Sigma Tau Ind Farmaceuti Utilizacao de pentraxina longa ptx3 para o tratamento de infertilidade feminina
WO2003035111A1 (en) 2001-10-24 2003-05-01 Sciclone Pharmaceuticals, Inc. Antiretroviral compositions comprising thymosin alpha peptides and protease inhibitors
ITRM20030596A1 (it) 2003-12-23 2005-06-24 Sigma Tau Ind Farmaceuti Uso di inibitori della pentraxina lunga ptx3, per la preparazione di un medicamento per la prevenzione e cura di patologie che rispondono all'inibizione dell'attivita' biologica di detta ptx3.
EP1832295A1 (en) * 2006-03-10 2007-09-12 Tecnogen S.P.A. Use of PTX3 for the treatment of viral diseases

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010012830A1 (en) * 1993-06-02 2001-08-09 Sciclone Pharmaceuticals, Inc. Combination therapy method for treating chronic hepatitis B
WO1999032516A2 (en) * 1997-12-19 1999-07-01 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Pharmaceutical compositions containing the long pentraxin ptx3
WO2004094991A2 (en) * 2003-04-23 2004-11-04 Sciclone Pharmaceuticals, Inc. Treatment or prevention of respiratory viral infections with alpha thymosin peptides

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
The Journal of Infectious Diseases, Vol. 185, pages 854-860 (2002) *
The Journal of Infectious Diseases, Vol. 185, pages 854-860 (2002)*

Also Published As

Publication number Publication date
DK2012816T3 (da) 2012-09-03
BRPI0711136A2 (pt) 2011-08-30
US8337828B2 (en) 2012-12-25
CA2649063C (en) 2014-11-25
WO2007128647A1 (en) 2007-11-15
HRP20120676T1 (hr) 2012-09-30
MX2008013872A (es) 2008-11-14
SI2012816T1 (sl) 2012-09-28
AU2007247292A1 (en) 2007-11-15
US20090275508A1 (en) 2009-11-05
CN101437535A (zh) 2009-05-20
ES2389452T3 (es) 2012-10-26
EP2012816A1 (en) 2009-01-14
JP2009535373A (ja) 2009-10-01
RS52377B (sr) 2012-12-31
HK1128622A1 (en) 2009-11-06
PT2012816E (pt) 2012-08-17
PL2012816T3 (pl) 2012-11-30
KR20090007621A (ko) 2009-01-19
CN101437535B (zh) 2013-01-30
CY1113277T1 (el) 2016-04-13
AU2007247292B2 (en) 2012-04-05
CA2649063A1 (en) 2007-11-15
JP5441685B2 (ja) 2014-03-12
EP2012816B1 (en) 2012-06-27

Similar Documents

Publication Publication Date Title
KR101380360B1 (ko) 거대세포바이러스 감염의 치료를 위한, 단독으로 또는 피티엑스 3 또는 강시클로비어와 병용되는 티모신 알파1의 용도
US8268304B2 (en) Use of the long pentraxin PTX3 for the prevention or treatment of viral diseases
US8357692B2 (en) Methods of treatment of bone degenerative diseases
EP4121092B1 (en) Hybrid interferons for treating viral infections
HK1128622B (en) USE OF THYMOSIN α1, ALONE OR IN COMBINATION WITH PTX3 OR GANCICLOVIR, FOR THE TREATMENT OF CYTOMEGALOVIRUS INFECTION
CN115835877A (zh) 病毒感染引起的器官衰竭的预防和治疗
HK1173983B (en) Use of the long pentraxin ptx3 for the prevention or treatment of viral diseases
HK1129301B (en) Use of the long pentraxin ptx3 for the prevention or treatment of viral diseases
HK40082469A (en) Hybrid interferons for treating viral infections
HK40082469B (en) Hybrid interferons for treating viral infections

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

R17-X000 Change to representative recorded

St.27 status event code: A-5-5-R10-R17-oth-X000

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20170325

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20170325